AzorinJM, SpiegelR, RemingtonG, VanelleJM, PéréJJ, GiguereM, BourdeixI. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry, 158:1305–1313. 2001.
2.
CooperLT. Myocarditis. N Engl J Med, 360:1526–1538. 2009.
3.
CorrellCU, ManuP, OlshanskiyV, NapolitanoB, KaneJM, MalhotraAK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302:1765–1773. 2009.
4.
CoulterDM, BateA, MeyboomRH, LindquistM, EdwardsIR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: Data mining study. BMJ, 322:1207–1209. 2001.
5.
FloreaniJ, BastiampillaiT. Successful re-challenge with clozapine following development of clozapine-induced cardiomyopathy. Aust N Z J Psychiatry, 42:747–748. 2007.
6.
FontanaPG, SümegiB. Association of Clozaril (clozapine) with cardiovascular toxicity [Dear Healthcare Professional letter]Quebec: Novartis Pharmaceuticals Canada Inc, 2002.
7.
KumraS, OberstarJV, SikichL, FindlingRL, McClellanJM, VinogradovS, Charles SchulzS. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull, 34:60–71. 2008c.
8.
LaylandJJ, LiewD, PriorDL. Clozapine-induced cardiotoxicity: A clinical update. Med J Aust, 190:190–192. 2009.
9.
MeltzerHY, BoboWV, RoyA, JayathilakeK, ChenY, ErtugrulA, Anil YağcioğluAE, SmallJG. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry, 69:274–285. 2008.
10.
MerrillDB, AhmariSE, BradfordJM, LiebermanJA. Myocarditis during clozapine treatment. Am J Psychiatry, 163:204–208. 2006.
11.
RostagnoC, Di NorsciaG, PlacidiGF, GensiniGF. Beta-blocker and angiotensin-converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine. Gen Hosp Psychiatry, 30:280–283. 2008.
TangWK, UngvariGS. Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: A prospective open trial. Prog Neuropsychopharmacol Biol Psychiatry, 27:373–379. 2003.
14.
VolavkaJ, CzoborP, SheitmanB, LindenmayerJP, CitromeL, McEvoyJP, CooperTB, ChakosM, LiebermanJA. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry, 159:255–262. 2002.
